Dexcom is hoping to win FDA approval to begin selling its G7 continuous glucose monitor in the U.S. later this year. (Shown here with an Apple Watch). · MedTech Dive · Courtesy of Dexcom The above ...

DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence. Read why DXCM stock is a Buy.

Dexcom G7 15 Day arrives in Canada in November with longer sensor wear and expanded insurance coverage. Here's what users ...

DexCom (NasdaqGS:DXCM) has launched its Dexcom G7 15 Day Continuous Glucose Monitoring System in Canada, following Health ...

DexCom, Inc. said on October 28, 2026 that its Dexcom G7 15 Day Continuous Glucose Monitoring System will be available in ...

Dexcom says stolen G7 sensors from two scrapped lots were sold through unauthorized channels, creating infection and reading-failure risks. Photo: Javier Zayas Photography/Getty Images Medical device ...

The upcoming system, for people with Type 1 or Type 2 diabetes ages 18 and up, boosts wear time by 50% over the currently available G7 sensor. (Dexcom) Dexcom has won a clearance from the FDA for its ...

Editor's note: This article has been updated with a comment from a Pharmsource spokesperson. Continuous glucose monitoring specialist Dexcom has identified two lots of Dexcom G7 sensors (1725204004 ...

Dexcom has discovered that certain lots of its Dexcom G7 sensors that were supposed to be scrapped and destroyed were actually stolen during the destruction process and sold by third parties. Stolen ...

Editor’s note: This post was updated on June 9 to include a statment from Pharmsource. People with diabetes who use the Dexcom G7 continuous glucose monitoring system need to check the lot numbers on ...